__NUXT_JSONP__("/drugs/Rexinoid_NRX_194204", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"260262-39-3",chebiId:b,chemicalFormula:b,definition:"An orally bioavailable synthetic retinoid X receptor (RXR) agonist with potential antineoplastic and anti-inflammatory activities. Rexinoid NRX 194204 selectively binds to and activates RXRs. Because RXRs can form heterodimers with several nuclear receptors (NRs), RXR activation by this agent may result in a broad range of gene expression depending on the effector DNA response elements activated. Rexinoid NRX 194204 may inhibit the tumor-necrosis factor (TNF)-mediated release of nitric oxide (NO) and interleukin 6 (IL6) and may inhibit tumor cell proliferation. This agent appears to be less toxic than RAR-selective ligands.",fdaUniiCode:"877M97Z38Y",identifier:"C74076",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C804"],synonyms:["AGN194204","NRX194204",c,"VTP-194204"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRexinoid_NRX_194204",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Rexinoid_NRX_194204","","Rexinoid NRX 194204","2021-10-30T13:44:21.723Z")));